ACTRN12613001060730终止2 期
A Phase 2 Multi-Centre Study to Characterise the Pharmacodynamics of Vessel Dilator Peptide (VSDL) in Patients with Acute Decompensated Congestive Heart Failure to be assessed by effects on renal function.
适应症
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 65
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Patients who are hospitalised with acute decompensated congestive heart failure and
- •LVEF = 45% and
- •GFR 25-90 mls/min as assessed by Cockcroft and Gault and
- •NTproBNP > 1000pg/mL and
- •Must be able to be hospitalised for a further 72 hours post-IV infusion.
- •Non-pregnant females
- •Signed Informed consent
排除标准
- •Acute ST elevation myocardial infarction (STEMI)
- •Pulmonary embolism (PE)
- •Severe valvular heart disease
- •B/P < 90mm Hg.
- •Congenital heart defects
- •Cardiac surgery within 4 weeks
- •Cerebrovascular accident within 4 weeks
- •Presence of hepatic impairment
研究者
相似试验
已完成
2 期
A Prospective Phase II Multicenter Study for Prophylaxis of Acute Exacerbations of Interstitial Lung Disease after Lung Cancer ResectioInterstitial pneumonia Lung cancerJPRN-UMIN000008277Yokohama Consortium of Thoracic Surgeons70
进行中（未招募）
不适用
A phase 2a, multi-centre, controlled study of the safety and efficacy of wound healing gel I-020502 in patients undergoing autologous meshed skin grafting. - Acute WoundsEUCTR2006-005092-18-DEKUROS BIOSURGERY AG10
已完成
不适用
A Prospective, Multi-center Investigation of the performance of Endo GIA Reinforced Reload with Tri-Staple Technology in Gastrectomy for Gastric CancerGastric CancerJPRN-UMIN000014398Aichi Cancer Center Hospital, Department of Gastrointestinal Surgery100
进行中（未招募）
不适用
A multi-centre, open-label, phase II study of the safety, efficacy and pharmacokinetic (PK) profile of CAP-232 administered through continuous intravenous infusion in patients with metastatic kidney cancerEUCTR2006-004857-86-FRCaprion Pharmaceuticals Inc.40
已完成
不适用
A multi-center proof-of-concept phase2 study of encorafenib + binimetinib + cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancerColorectal cancerJPRN-UMIN000031857ational Cancer Center Hospital Eas36